Anti-HMGCR myopathy: estimated five-fold higher incidence in Polynesian compared with European populations in Aotearoa/New Zealand
Authors' conclusion
In the past half decade the estimated incidence of anti-HMGCR myopathy in New Zealand has doubled. Polynesian peoples of New Zealand >40 years old have an estimated 5-fold higher risk compared with European and Asian peoples. The estimated absolute risk in statin users >40 years old was 108 cases/million/year in Polynesians vs 21 cases/million/year in Europeans.
Study context
- Population
- New Zealand; seropositivity for immunoprecipitating anti-HMGCR autoantibodies tested at a national reference laboratory, 1 October 2019 to 30 September 2021all >40 years, all prior statin use
- Participants
- 40 participants
- Exposure
- Polynesian vs Asian vs European ethnicity, aged >40 years
- Outcome
- Population incidence of anti-HMGCR myopathy and ethnic variation in those aged >40 years
Methodological detailsnational reference laboratory incidence cohort, hospital discharge data (ICD-10 AM M60.8/M60.9) examined for concordance
- National reference laboratory incidence cohort
- Hospital discharge data (ICD-10 AM M60.8/M60.9) examined for concordance
Main finding
As reported in the abstract
Annual incidence of anti-HMGCR myopathy
- Overall annual incidence (95% CI 2.8-5.5), cases/million/year
- 4
Observational data: associations, not effects.
Further findings
| Outcome | Polynesians | Europeans |
|---|---|---|
| Risk in statin users aged >40 years | ∼1/9000 | ∼1/48 000 |
Idiopathic and unspecified myopathy (ICD AM M60.8/M60.9) in hospital discharges
- Ethnic difference in incidence also found
Original publication
Anti-HMGCR myopathy: estimated five-fold higher incidence in Polynesian compared with European populations in Aotearoa/New Zealand. Rheumatology (Oxford). Published 25 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →